Novo Nordisk’s stock plunged Tuesday after the maker of diabetes and weight-loss drugs Ozempic and Wegovy said it expects sales to fall by a lot more than analysts projected.

The stock tumbled 19% at the opening bell in Copenhagen after its outlook for the year ahead disappointed investors.

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN, Feb 4 (Reuters) - Novo Nordisk's shares plunged as much as 20% ...

Just as Novo Nordisk showed signs of a recovery, another cold shower hit investors as the drugmaker surprise prereleased its ...

The company is banking on its Wegovy pill and next-generation weight loss injectable CagriSema to recapture share of the key ...

COPENHAGEN, Feb 3 (Reuters) - Wegovy maker Novo Nordisk expects a decline in sales this year, it said on Tuesday, a new ...

Novo Nordisk’s U.S.-traded shares slid 13% Tuesday after the drugmaker unexpectedly warned that its 2026 sales would decline more sharply than expected, as pricing pressure weighs on U.S. sales of its ...

Novo Nordisk just introduced a GLP-1 pill, but the company makes more than just weight-loss drugs.

By Harshita Mary Varghese and Patrick Wingrove Jan 28 (Reuters) - Novo Nordisk spent nearly $500 million on U.S. advertising ...

ALLEROD, Denmark, Jan 30 (Reuters) - A play examining the meteoric rise of Danish weight-loss drug giant Novo Nordisk will ...

Danish pharmaceutical giant Novo Nordisk said yesterday that it expects 2026 sales to slide by up to 13 per cent as prices ...

Shares in Novo Nordisk opened sharply lower on Wednesday, after the obesity drug specialist warned of thinning sales and profits.